Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Tuesday ...

UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data The findings, published Tuesday in Nature, are important for another key reason. The team’s work originally ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

เช็คตัวเอง! อาการจากฝุ่นPM2.5 แบบไหนต้องไปพบแพทย์! หลังฝุ่นPM2.5 กลับมาอีกระลอก ส่งผลต่อสุขภาพ ...

อาการประชวรโป๊ปฟรานซิสทรุดหนัก วาติกันระบุ ‘ขั้นวิกฤต’ เป็นครั้งแรก เมื่อวันที่ 24 ...